Biogen's ($BIIB) recent early-stage success in Alzheimer's disease has galvanized R&D in the field, and Roche ($RHHBY), owner of a similar treatment, is considering whether to tee off another Phase III trial for its once-failed antibody. Like Biogen's candidate, Roche's gantenerumab targets beta-amyloid proteins, blasting away the buildups in an effort to slow the cognitive decline that characterizes Alzheimer's. The injection failed to beat out placebo in a Phase III study Roche terminated last year, but Biogen's ability to show efficacy in a Phase I trial has the Swiss drugmaker considering a do-over, Bloomberg reports. Roche is also developing a second amyloid-targeting antibody, crenezumab, alongside AC Immune. News